Navigation Links
Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
Date:11/4/2008

BETHESDA, Md., Nov. 4 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, presented data from a preclinical study(1) showing cytotoxic activity of anti-EpCAM antibody adecatumumab (MT201) against KRAS-mutated human colon cancer cells on November 1, 2008 at the 23rd Annual meeting of the International Society for Biological Therapy of Cancer (iSBTc) , taking place October 31-November 2, 2008 in San Diego, California.

The new preclinical data indicated that human colon cancer cells are efficiently eliminated in tested cell lines by adecatumumab, mediated by antibody-dependent cellular cytotoxicity (ADCC), irrespective of their KRAS mutation status. Recent studies suggest that anti-EGFR antibodies cetuximab (Erbitux(R); ImClone, BMS, Merck KGaA) and panitumumab (Vectibix(R); Amgen) are beneficial for patients with KRAS wild-type tumors, however, show limited or no efficacy in the treatment of colon cancer patients with a mutated KRAS oncogene in their cancer cells. These findings recently led to the approval of cetuximab for first-line therapy in patients with KRAS wild-type tumors. As a consequence, there is a high need for the development of treatment strategies covering those patients who are not able to benefit from this important new treatment option as their tumors carry the KRAS mutated gene. This mutation is found in approximately 35 to 40 percent of patients with this disease.

"Given that more than 95 percent of colon cancer patients strongly express EpCAM on their tumors, and that 35 to 40 percent of patients who have a KRAS mutant tumor may not benefit from treatment with anti-EGFR antibodies, adecatumumab could be investigated as a potential alternative for the treatment of KRAS mutant colon cancer tumors," commented Patrick Baeuerle, senior vice president and chief scientific officer for Micromet.
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Announces Changes in Management Team
2. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
3. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
4. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
5. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
6. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
7. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
8. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
9. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
10. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
11. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... 2015 Research and Markets ( ... Report on China,s Sodium Ibandronate Market, 2010-2019" report to ... clinic under the trade name of Bondronat in ... 1996, sodium ibandronate was approved by the FDA to come ... the trade name of Boniva. However, since drug makers later ...
(Date:9/4/2015)... , September 4, 2015 ... today announces that Hutchison MediPharma Limited ("HMP"), its ... in the second proof-of-concept ("POC") trial of fruquintinib ... cancer ("NSCLC") in China . ... succeeded in meeting the primary efficacy endpoint of ...
(Date:9/3/2015)... , Sept. 3, 2015 ... New Guide to that Market, its R&D and Sales Potentials ... assess the future of cancer-treating medicines? Visiongain,s new report gives ... stay ahead. There you discover financial data, R&D trends, opportunities, ... In our analysis you see forecasted sales to 2025 ...
Breaking Medicine Technology:Investigation Report on China's Sodium Ibandronate Market 2010-2019 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 3World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 2World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 3World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 4World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 5World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 6World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 7
... Reportlinker.com announces that a new market research ... Chinese Markets for Bladder Cancer Treatment Drugs ... , China,s demand ... a fast pace in the past decade. In ...
... , REDMOND, Wash., Nov. 3 Medical software company ... availability of FiatLux Visualize(TM) Free, advanced 2D/3D visualization software ... is available for any healthcare professional via download from ... , "There is tremendous unrealized potential in medical ...
Cached Medicine Technology:Reportlinker Adds Chinese Markets for Bladder Cancer Treatment Drugs 2Reportlinker Adds Chinese Markets for Bladder Cancer Treatment Drugs 3Reportlinker Adds Chinese Markets for Bladder Cancer Treatment Drugs 4Reportlinker Adds Chinese Markets for Bladder Cancer Treatment Drugs 5Free 2D/3D Advanced Visualization Software for CT and MRI Now Available From FiatLux Imaging 2
(Date:9/4/2015)... ... September 04, 2015 , ... ... is now available at CitiDent. CEREC is a newer method for creating restorations ... time for patients by eliminating the need for multiple appointments, CEREC produces restorations ...
(Date:9/4/2015)... ... September 04, 2015 , ... Many consumers are looking for a quick and convenient way to ... The patent-pending K Med Cups provide a quick and simple way to brew a hot ... flu or cough. As a result, they enhance comfort and health. The invention features a ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... ... on: the microbiome taking place in Hollywood, Florida October 9-10, 2015 at the ... Speakers at the 2015 symposium are doctors and researchers at the top of ...
(Date:9/4/2015)... , ... September 04, 2015 , ... Lalonde Gordon ran ... and followed up with victory in the men’s 400 meters final, with an impressive ... and Field Championships in San Jose, Costa Rica in August 2015. The 44.64 time ...
(Date:9/4/2015)... Texas (PRWEB) , ... September 04, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at ... he says are prophetic details involving the Pope’s upcoming trip to the United States. , ... details what his role with the Vatican and society is. Yisrayl also provides the meaning ...
Breaking Medicine News(10 mins):Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3Health News:Yisrayl Hawkins Writes Open Letter to Pope Francis In Light of Approaching U.S. Visit 2
... months of life, but not fetal growth, is associated with ... to a new study from The Generation R Study Group ... that low birth weight is associated with an increased risk ... fetal and infant growth patterns on this risk had not ...
... , THURSDAY, Jan. 19 (HealthDay News) -- Many ... tract, a problem that can cause serious health problems and ... said their findings show that more needs to be done ... in the esophagus, stomach or first part of the intestine ...
... growing need for family-friendly workplace policies, a new study ... with support from the Rockefeller Foundation, concludes that providing ... outcomes for working families, businesses and the public. ... Work at Rutgers, the State University of New Jersey, ...
... Reporter , THURSDAY, Jan. 19 (HealthDay News) -- The number ... for HIV infection has declined significantly, federal health officials reported ... sexual or drug-related behavior dropped from 13 percent of men ... and 8 percent, respectively, in 2010, according to the U.S. ...
... of autism is now well established, a growing body of ... in this serious developmental disorder affecting nearly one in 100 ... that low birth weight is an important environmental factor contributing ... "Our study of discordant twins -- twin pairs in which ...
... cause of blindness in the Western World. A report from ... today shows the number of new cases of blindness and ... last ten years. The study just published in ... 11,848 new cases of legal blindness. The rate of blindness ...
Cached Medicine News:Health News:Accelerated infant growth increases risk of future asthma symptoms in children 2Health News:Kidney Failure Patients Prone to GI Tract Bleeding 2Health News:Rutgers study finds paid family leave leads to positive economic outcomes 2Health News:Rutgers study finds paid family leave leads to positive economic outcomes 3Health News:More Americans Practicing Safe Sex, CDC Reports 2Health News:More Americans Practicing Safe Sex, CDC Reports 3Health News:Another clue in the mystery of autism 2Health News:Report shows risk of blindness halved over last decade 2
... 48-capillary 3730 DNA Analyzer, upgradeable to 96 ... DNA analysis. , Higher optical sensitivity ... higher-quality data at a lower cost. , ... , Optimized polymers increase your productivity without ...
... this unique offer, you can ... application. Pipetman P2 and P10 ... reagents, and P100 is perfect ... Filter Tips, which are especially ...
... is an immunochromatography based one step ... qualitative determination of Methamphetamine in human ... 1000 ng/mL. This assay has not ... care,location and is for use by ...
... The RapidAMP test is an ... test. It is,designed for qualitative determination ... above,a cut-off level of 1000 ng/mL. ... in the point of care,location and ...
Medicine Products: